Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).

[1]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[2]  M. Shlipak,et al.  Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  A. Cheung,et al.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. , 2011, Journal of the American Society of Nephrology : JASN.

[4]  Mark Woodward,et al.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. , 2011, Kidney international.

[5]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[6]  E. Rimm,et al.  Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. , 2011, American heart journal.

[7]  J. Ix.  New insights to fibroblast growth factor 23 in kidney transplant. , 2011, Journal of the American Society of Nephrology : JASN.

[8]  M. Wolf,et al.  Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. , 2011, Journal of the American Society of Nephrology : JASN.

[9]  M. Shlipak,et al.  Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. , 2011, JAMA.

[10]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[11]  S. Cummings,et al.  Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. , 2010, American journal of epidemiology.

[12]  M. Shlipak,et al.  Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  H. Melhus,et al.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. , 2009, Atherosclerosis.

[14]  B. Kestenbaum,et al.  25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. , 2009, Journal of the American Society of Nephrology : JASN.

[15]  Thomas J. Wang,et al.  Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.

[16]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[17]  R. Foley,et al.  Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. , 2008, American heart journal.

[18]  B. Boehm,et al.  Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.

[19]  C. Schmid,et al.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[21]  L. Quarles,et al.  How fibroblast growth factor 23 works. , 2007, Journal of the American Society of Nephrology : JASN.

[22]  R. D'Agostino,et al.  Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. , 2007, Archives of internal medicine.

[23]  M. Shlipak,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.

[24]  B. Kestenbaum,et al.  Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease , 2006, Annals of Internal Medicine.

[25]  S. Cummings,et al.  Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. , 2006, Archives of internal medicine.

[26]  S. Cummings,et al.  Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  S. Jan de Beur.  Tumor-induced osteomalacia. , 2005, JAMA.

[28]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[29]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[30]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[31]  L. Fried,et al.  Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.

[32]  E. Vittinghoff,et al.  Predictors of Heart Failure Among Women With Coronary Disease , 2004, Circulation.

[33]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[34]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[35]  C. Furberg,et al.  Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. , 2001, Journal of the American College of Cardiology.

[36]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[37]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[38]  L. Kuller,et al.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.

[39]  J. Gardin,et al.  Assessment of cerebrovascular disease in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[40]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[41]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[42]  I. D. de Boer,et al.  Cystatin C identifies chronic kidney disease patients at higher risk for complications. , 2011, Journal of the American Society of Nephrology : JASN.

[43]  R. Garrick.  Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly , 2010 .

[44]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[45]  M. Cheitlin,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2008 .